title: Nebivolol can be used for combination therapy in patients with autosomal dominant polycystic kidney disease.
authors.affiliation: a Department of Internal Medicine, Division of Nephrology , Erciyes University School of Medicine , Kayseri , Turkey.
authors.forename: Ismail
authors.initials: I
authors.lastname: Kocyigit
authors.affiliation: a Department of Internal Medicine, Division of Nephrology , Erciyes University School of Medicine , Kayseri , Turkey.
authors.forename: Eray
authors.initials: E
authors.lastname: Eroglu
authors.affiliation: b Department of Internal Medicine, Division of Nephrology , Istanbul Bilim University School of Medicine , Istanbul , Turkey.
authors.forename: Tevfik
authors.initials: T
authors.lastname: Ecder
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D006973:Hypertension; D000068577:Nebivolol; D016891:Polycystic Kidney, Autosomal Dominant
chemical_list: D000068577:Nebivolol
keywords: Nebivolol; endothelial dysfunction; hypertension; polycystic kidney disease